Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164


Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018.

Badolo A, Burt F, Daniel S, Fearns R, Gudo ES, Kielian M, Lescar J, Shi Y, von Brunn A, Weiss SR, Hilgenfeld R.

Antiviral Res. 2019 Feb;162:142-150. doi: 10.1016/j.antiviral.2018.12.015. Epub 2018 Dec 28. Review.


The Structure of the Zika Virus Protease, NS2B/NS3pro.

Hilgenfeld R, Lei J, Zhang L.

Adv Exp Med Biol. 2018;1062:131-145. doi: 10.1007/978-981-10-8727-1_10. Review.


Viral Entry and NS1 as Potential Antiviral Drug Targets.

de Silva AM, Rey FA, Young PR, Hilgenfeld R, Vasudevan SG.

Adv Exp Med Biol. 2018;1062:107-113. doi: 10.1007/978-981-10-8727-1_8. Review.


Crystal structure of the C-terminal fragment of NS1 protein from yellow fever virus.

Wang H, Han M, Qi J, Hilgenfeld R, Luo T, Shi Y, Gao GF, Song H.

Sci China Life Sci. 2017 Dec;60(12):1403-1406. doi: 10.1007/s11427-017-9238-8. Epub 2017 Nov 29. No abstract available.


Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein.

Lei J, Kusov Y, Hilgenfeld R.

Antiviral Res. 2018 Jan;149:58-74. doi: 10.1016/j.antiviral.2017.11.001. Epub 2017 Nov 8. Review.


STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease.

Schöne T, Grimm LL, Sakai N, Zhang L, Hilgenfeld R, Peters T.

Antiviral Res. 2017 Oct;146:174-183. doi: 10.1016/j.antiviral.2017.09.008. Epub 2017 Sep 18.


RNA-virus proteases counteracting host innate immunity.

Lei J, Hilgenfeld R.

FEBS Lett. 2017 Oct;591(20):3190-3210. doi: 10.1002/1873-3468.12827. Epub 2017 Sep 15. Review.


Lybatides from Lycium barbarum Contain An Unusual Cystine-stapled Helical Peptide Scaffold.

Tan WL, Wong KH, Lei J, Sakai N, Tan HW, Hilgenfeld R, Tam JP.

Sci Rep. 2017 Jul 12;7(1):5194. doi: 10.1038/s41598-017-05037-1.


Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.

Kouretova J, Hammamy MZ, Epp A, Hardes K, Kallis S, Zhang L, Hilgenfeld R, Bartenschlager R, Steinmetzer T.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):712-721. doi: 10.1080/14756366.2017.1306521.


Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.

Jadav SS, Sinha BN, Hilgenfeld R, Jayaprakash V.

Curr Comput Aided Drug Des. 2017 Nov 10;13(4):346-361. doi: 10.2174/1573409913666170309145308. Review.


Extended substrate specificity and first potent irreversible inhibitor/activity-based probe design for Zika virus NS2B-NS3 protease.

Rut W, Zhang L, Kasperkiewicz P, Poreba M, Hilgenfeld R, Drąg M.

Antiviral Res. 2017 Mar;139:88-94. doi: 10.1016/j.antiviral.2016.12.018. Epub 2016 Dec 26.


Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology.

Nitsche C, Zhang L, Weigel LF, Schilz J, Graf D, Bartenschlager R, Hilgenfeld R, Klein CD.

J Med Chem. 2017 Jan 12;60(1):511-516. doi: 10.1021/acs.jmedchem.6b01021. Epub 2016 Dec 14.


Coxsackievirus B3 protease 3C: expression, purification, crystallization and preliminary structural insights.

Fili S, Valmas A, Christopoulou M, Spiliopoulou M, Nikolopoulos N, Lichière J, Logotheti S, Karavassili F, Rosmaraki E, Fitch A, Wright J, Beckers D, Degen T, Nénert G, Hilgenfeld R, Papageorgiou N, Canard B, Coutard B, Margiolaki I.

Acta Crystallogr F Struct Biol Commun. 2016 Dec 1;72(Pt 12):877-884. Epub 2016 Nov 25.


Zika virus NS1, a pathogenicity factor with many faces.

Hilgenfeld R.

EMBO J. 2016 Dec 15;35(24):2631-2633. Epub 2016 Oct 27. No abstract available.


Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments.

Becker D, Kaczmarska Z, Arkona C, Schulz R, Tauber C, Wolber G, Hilgenfeld R, Coll M, Rademann J.

Nat Commun. 2016 Sep 28;7:12761. doi: 10.1038/ncomms12761.


p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.

Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfeld R, von Brunn A.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5192-201. doi: 10.1073/pnas.1603435113. Epub 2016 Aug 12.


Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor.

Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R.

Science. 2016 Jul 29;353(6298):503-5. doi: 10.1126/science.aag2419. Epub 2016 Jul 7.


Production, crystallization and X-ray diffraction analysis of the protease CT441 from Chlamydia trachomatis.

Kohlmann F, Shima K, Rupp J, Solbach W, Hilgenfeld R, Hansen G.

Acta Crystallogr F Struct Biol Commun. 2015 Dec;71(Pt 12):1454-8. doi: 10.1107/S2053230X15020518. Epub 2015 Nov 18.


Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L.

Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. doi: 10.1128/AAC.01375-15. Epub 2015 Sep 14.


Structures of DegQ from Legionella pneumophila Define Distinct ON and OFF States.

Schubert A, Wrase R, Hilgenfeld R, Hansen G.

J Mol Biol. 2015 Aug 28;427(17):2840-51. doi: 10.1016/j.jmb.2015.06.023. Epub 2015 Jul 20.


A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARS-coronavirus replication-transcription complex.

Kusov Y, Tan J, Alvarez E, Enjuanes L, Hilgenfeld R.

Virology. 2015 Oct;484:313-22. doi: 10.1016/j.virol.2015.06.016. Epub 2015 Jul 3.


The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.

Lacroix C, George S, Leyssen P, Hilgenfeld R, Neyts J.

Antimicrob Agents Chemother. 2015 Sep;59(9):5814-8. doi: 10.1128/AAC.00534-15. Epub 2015 Jun 8.


Crystal Structure of the Peroxo-diiron(III) Intermediate of Deoxyhypusine Hydroxylase, an Oxygenase Involved in Hypusination.

Han Z, Sakai N, Böttger LH, Klinke S, Hauber J, Trautwein AX, Hilgenfeld R.

Structure. 2015 May 5;23(5):882-892. doi: 10.1016/j.str.2015.03.002. Epub 2015 Apr 9.


Thiazolidone derivatives as inhibitors of chikungunya virus.

Jadav SS, Sinha BN, Hilgenfeld R, Pastorino B, de Lamballerie X, Jayaprakash V.

Eur J Med Chem. 2015 Jan 7;89:172-8. doi: 10.1016/j.ejmech.2014.10.042. Epub 2014 Oct 16.


Acquisition of new protein domains by coronaviruses: analysis of overlapping genes coding for proteins N and 9b in SARS coronavirus.

Shukla A, Hilgenfeld R.

Virus Genes. 2015 Feb;50(1):29-38. doi: 10.1007/s11262-014-1139-8. Epub 2014 Nov 20.


Structural basis of the proteolytic and chaperone activity of Chlamydia trachomatis CT441.

Kohlmann F, Shima K, Hilgenfeld R, Solbach W, Rupp J, Hansen G.

J Bacteriol. 2015 Jan 1;197(1):211-8. doi: 10.1128/JB.02140-14. Epub 2014 Oct 27.


The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.

Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J.

Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. doi: 10.1128/AAC.03328-14. Epub 2014 Sep 8.


From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design.

Hilgenfeld R.

FEBS J. 2014 Sep;281(18):4085-96. doi: 10.1111/febs.12936. Epub 2014 Aug 11. Review.


Accessory proteins of SARS-CoV and other coronaviruses.

Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R.

Antiviral Res. 2014 Sep;109:97-109. doi: 10.1016/j.antiviral.2014.06.013. Epub 2014 Jul 1. Review.


Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features.

Lei J, Mesters JR, Drosten C, Anemüller S, Ma Q, Hilgenfeld R.

Antiviral Res. 2014 Sep;109:72-82. doi: 10.1016/j.antiviral.2014.06.011. Epub 2014 Jun 30.


The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.

Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D.

Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.


The evolution of insulin glargine and its continuing contribution to diabetes care.

Hilgenfeld R, Seipke G, Berchtold H, Owens DR.

Drugs. 2014 Jun;74(8):911-27. doi: 10.1007/s40265-014-0226-4. Review.


Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases.

van der Linden L, Ulferts R, Nabuurs SB, Kusov Y, Liu H, George S, Lacroix C, Goris N, Lefebvre D, Lanke KH, De Clercq K, Hilgenfeld R, Neyts J, van Kuppeveld FJ.

Antiviral Res. 2014 Mar;103:17-24. doi: 10.1016/j.antiviral.2013.12.012. Epub 2014 Jan 4.


Improving experimental phases for strong reflections prior to density modification.

Uervirojnangkoorn M, Hilgenfeld R, Terwilliger TC, Read RJ.

Acta Crystallogr D Biol Crystallogr. 2013 Oct;69(Pt 10):2039-49. doi: 10.1107/S0907444913018167. Epub 2013 Sep 20.


The structure of a glycoside hydrolase family 81 endo-β-1,3-glucanase.

Zhou P, Chen Z, Yan Q, Yang S, Hilgenfeld R, Jiang Z.

Acta Crystallogr D Biol Crystallogr. 2013 Oct;69(Pt 10):2027-38. doi: 10.1107/S090744491301799X. Epub 2013 Sep 20.


From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.

Hilgenfeld R, Peiris M.

Antiviral Res. 2013 Oct;100(1):286-95. doi: 10.1016/j.antiviral.2013.08.015. Epub 2013 Sep 6. Review.


Helix unfolding/refolding characterizes the functional dynamics of Staphylococcus aureus Clp protease.

Ye F, Zhang J, Liu H, Hilgenfeld R, Zhang R, Kong X, Li L, Lu J, Zhang X, Li D, Jiang H, Yang CG, Luo C.

J Biol Chem. 2013 Jun 14;288(24):17643-53. doi: 10.1074/jbc.M113.452714. Epub 2013 Apr 26.


3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.

Tan J, George S, Kusov Y, Perbandt M, Anemüller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P, Neyts J, Hilgenfeld R.

J Virol. 2013 Apr;87(8):4339-51. doi: 10.1128/JVI.01123-12. Epub 2013 Feb 6.


Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease.

Hammamy MZ, Haase C, Hammami M, Hilgenfeld R, Steinmetzer T.

ChemMedChem. 2013 Feb;8(2):231-41. doi: 10.1002/cmdc.201200497. Epub 2013 Jan 10.


Virus-host interactomes--antiviral drug discovery.

Ma-Lauer Y, Lei J, Hilgenfeld R, von Brunn A.

Curr Opin Virol. 2012 Oct;2(5):614-21. doi: 10.1016/j.coviro.2012.09.003. Review.


Single-drop optimization of protein crystallization.

Meyer A, Dierks K, Hilterhaus D, Klupsch T, Mühlig P, Kleesiek J, Schöpflin R, Einspahr H, Hilgenfeld R, Betzel C.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Aug 1;68(Pt 8):994-8. doi: 10.1107/S1744309112024074. Epub 2012 Jul 31.


Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H.

ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. Review.


Architecture and regulation of HtrA-family proteins involved in protein quality control and stress response.

Hansen G, Hilgenfeld R.

Cell Mol Life Sci. 2013 Mar;70(5):761-75. doi: 10.1007/s00018-012-1076-4. Epub 2012 Jul 18. Review.


Structural and mechanistic analysis of the membrane-embedded glycosyltransferase WaaA required for lipopolysaccharide synthesis.

Schmidt H, Hansen G, Singh S, Hanuszkiewicz A, Lindner B, Fukase K, Woodard RW, Holst O, Hilgenfeld R, Mamat U, Mesters JR.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6253-8. doi: 10.1073/pnas.1119894109. Epub 2012 Apr 2.


Nonstructural proteins 7 and 8 of feline coronavirus form a 2:1 heterotrimer that exhibits primer-independent RNA polymerase activity.

Xiao Y, Ma Q, Restle T, Shang W, Svergun DI, Ponnusamy R, Sczakiel G, Hilgenfeld R.

J Virol. 2012 Apr;86(8):4444-54. doi: 10.1128/JVI.06635-11. Epub 2012 Feb 8.


The macromolecular complex of ICP and falcipain-2 from Plasmodium: preparation, crystallization and preliminary X-ray diffraction analysis.

Hansen G, Schwarzloh B, Rennenberg A, Heussler VT, Hilgenfeld R.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Nov 1;67(Pt 11):1406-10. doi: 10.1107/S1744309111034592. Epub 2011 Oct 27.


X-ray structure of the SH3 domain of the phosphoinositide 3-kinase p85β subunit.

Chen S, Xiao Y, Ponnusamy R, Tan J, Lei J, Hilgenfeld R.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Nov 1;67(Pt 11):1328-33. doi: 10.1107/S1744309111031691. Epub 2011 Oct 25.


The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.

Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pöhlmann S, Haas J, Drosten C, von Brunn A.

PLoS Pathog. 2011 Oct;7(10):e1002331. doi: 10.1371/journal.ppat.1002331. Epub 2011 Oct 27.


Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.

Zhu L, George S, Schmidt MF, Al-Gharabli SI, Rademann J, Hilgenfeld R.

Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11.


Supplemental Content

Loading ...
Support Center